Abstract
Background: Ovarian cancer typically presents at an advanced stage, has a poor prognosis, and is a leading cause of cancer-related deaths in women. Extracellular vesicles (EVs) are cell membrane-derived nanoparticles that function in specific cell- to-cell communication and are under development as novel drug delivery vehicles and modulators of the tumor microenvironment. Artificial cell-derived vesicles (ACDVs) from M1 macrophages are able to repolarize macrophages from a M2 to a M1 phenotype and target tumor cells in in vitro studies.
Results: In this study, we generated engineered EVs (EEVs) by membrane disruption of M1 macrophages (MEVs) with and without cisplatin to generate cisplatin-loaded MEVs (C-MEVs) and empty MEVs (E-MEVs), which we tested in an ovarian cancer mouse xenograft model. E-MEVs and C-MEVs exhibited significantly less weight loss and equivalent activity to cisplatin, with improved activity over controls.
Conclusions: Further development of MEVs for the treatment of ovarian cancer is warranted.
Document Type
Article
Publication Date
2025
Digital Object Identifier (DOI)
https://doi.org/10.1186/s12645-025-00337-y
Funding Information
Research supported by NCI T32 CA160003, Kentucky Network for Innovation & Commercial Grant 30481152221.
Repository Citation
Cao, Connie D.; McCorkle, J. Robert; Allison, Derek B.; Yan, Donglin; Hill, Kristen S.; Li, Lan; Jayswal, Rani; Schweer, David; Dietrich, Charles S. III; Ueland, Frederick R.; Richards, Christopher I.; and Kolesar, Jill M., "M1 macrophage‑engineered vesicles have anti‑cancer activity in ovarian cancer" (2025). Markey Cancer Center Faculty Publications. 439.
https://uknowledge.uky.edu/markey_facpub/439
Notes/Citation Information
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/.